Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs Givinostat (Primary)
- Indications Myeloproliferative disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Italfarmaco
- 12 Jul 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 12 Jul 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2022.
- 12 Jul 2019 Status changed from recruiting to active, no longer recruiting.